A short presentation on the role biosimilars can play in contributing to access to medicine

1. Pioneering novel approaches
to increase access for
patients worldwide
Richard Francis, Division Head & CEO Sandoz
Schaftenau, Austria
June 17, 2016
Sandoz

2. Sandoz
“We discover new ways to
improve and extend
people’s lives...”
“ ...by pioneering novel
approaches
to help people around
the world access high-
quality healthcare”
This is how we contribute to improving society’s
ability to support growing healthcare needs
Our purpose is to increase
access for patients
Business Use Only1

3. Sandoz
Business Use Only2
...and our
aspiration
is to reach
ONE BILLION
Sandoz reached 520 million
patient lives in 2015

4. Sandoz
Biosimilars are key to increasing
access to life-saving medicines
Business Use Only3
Oncology
Respiratory
Biosimilars
Anti-infectives
Region growth drivers
OTC
Sandoz FY
2015 sales
Of 11 filings
already
completed2
Q1 2016 cc
growth vs PY
Sandoz
access
drivers
USD
772m
6 +50%
1. Including retail business 2. 11th filing expected – infliximab

5. Sandoz
Biosimilars can play a
transformational role in healthcare
Business Use Only4
€49-98B
Expected cumulative savings from
biosimilars 2016-2020 in US+EU51
Generate savings for
healthcare systems
~104%
Increase in standard units of
filgrastim in the UK from 2008-2014
(post biosimilar launch)1
Improve patient access
Sandoz is committed to driving access to biosimilars and life-saving medicines
1. IMS Institute for Healthcare Informatics: Delivering on the Potential of Biosimilar Medicines. Date of Report: Mar 2016.